Sino Biopharmaceutical's (HKG:1177) attributable profit rose 50% to 3.50 billion yuan in 2024 from 2.33 billion yuan in 2023, according to a Thursday filing with the Hong Kong bourse.
Earnings per share at the drug company increased to 0.1913 yuan from 0.1259 yuan in the previous year.
Revenue grew 10% to 28.9 billion yuan from 26.2 billion yuan a year earlier.
The company declared a final dividend of HK$0.04 per share, higher than the HK$0.03 declared in 2023 and payable July 10 to shareholders on record as of June 23.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。